141080 — LigaChem Biosciences Balance Sheet
0.000.00%
- KR₩6tn
- KR₩6tn
- KR₩126bn
Annual balance sheet for LigaChem Biosciences, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 61,649 | 170,940 | 158,965 | 93,103 | 483,303 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 21,728 | 46,529 | 19,817 | 20,880 | 35,548 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 100,011 | 228,951 | 191,619 | 134,619 | 550,262 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 7,618 | 24,432 | 26,492 | 25,424 | 25,313 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 135,912 | 293,233 | 252,530 | 189,502 | 738,383 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 14,009 | 17,018 | 28,603 | 37,072 | 117,183 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 23,786 | 34,459 | 32,932 | 41,281 | 122,385 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| ESOP Debt Guarantee | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 112,126 | 258,775 | 219,599 | 148,221 | 615,998 |
| Total Liabilities & Shareholders' Equity | 135,912 | 293,233 | 252,530 | 189,502 | 738,383 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |